The Swiss digital health company QUMEA raises CHF 9 million in its Series A financing round. QUMEA specializes in intelligent early warning systems for healthcare providers. The funds mark a significant milestone in the progression of QUMEA’s long-term strategy. The investor group includes Zürcher Kantonalbank (ZKB), PB Invest (Schweiz), two family offices, and a growth loan from UBS.
In addition, this funding round is supported by all existing investors and was significantly oversubscribed. Moreover, the growth loan from UBS underscores the commercial scalability and confidence in QUMEA’s business and company development.
Cyrill Gyger, CEO of QUMEA, on the raising process and outcome: «We are grateful to have had multiple options for this financing round, which is not to be taken for granted in the current funding environment. We chose an investor structure that perfectly aligns with our values and long-term strategy. The trust and continued support of our investor base are invaluable. Now we are perfectly positioned to replicate our Swiss success in international markets.»
«QUMEA’s technological leadership, its anonymous and precise solution in combination with a consistent and strong business growth, has left a lasting impression on us.», says Yves Becker, Senior Investment Manager at ZKB. «I am impressed by QUMEA’s entrepreneurial approach, the exceptional quality of its leadership team, and the team’s unwavering commitment to their guiding principles. Our decision to invest with our scale-up ticket reflects our belief in QUMEA’s extraordinary market-fit and its potential to disrupt an important segment of the healthcare sector.»
Andreas Linder, Head of Corporate Clients Solothurn, UBS Switzerland AG: «QUMEA’s traction demonstrates that the company solves an urgent problem in patient care. Being awarded the SEF.Growth High Potential Label in 2023 is additional strong evidence for QUMEA’s potential to scale its business. As a founding partner of the SEF.Growth initiative, UBS is proud to support QUMEA’s continued growth with this loan.»
The funds are set to fuel QUMEA’s goal to achieve market leadership in selected international markets. Additionally, the funding will enhance QUMEA’s product strategy, particularly in strengthening and expanding its ‘Software as a Medical Device’ portfolio introduced in 2023, reinforcing its commitment to mission critical decision support.
About QUMEA
QUMEA is transforming care workflows with an intelligent, privacy-respecting mobility monitoring system. The system is used for proactive risk management in hospitals and long-term facilities. Use cases include, amongst others, fall detection, fall prevention, pressure ulcer prevention and medical decision support. QUMEA’s system empowers caregivers to be present for patients precisely when needed by providing early and actionable insights. With a reported average of 74% reduction in patient falls QUMEA sets new benchmarks in proactive care and prevention in demanding acute care environments, all while fully avoiding privacy-compromising cameras or microphones.
With a presence in over 80 facilities, including internationally leading institutions like the Hirslanden Group, University Geriatric Medicine Felix Platter Basel, Hannover Medical School, Balgrist University Hospital and Schulthess Clinic, QUMEA is recognized for its evidenced contribution to enhancing quality of care.
Employing a team of over 30 dedicated professionals, QUMEA operates out of its offices in Solothurn (Switzerland), Stockholm (Sweden), and Mannheim (Germany).
